In Silico Study for Similar FDA Approved Drugs as Inhibitors of SARS-CoV-2 Spike and the Host Receptor Proteins
The severe acute respiratory syndrome coronavirus 2, known as COVID-19, has been hideously increased worldwide. The disease began in Wuhan, China, around December 2019, then spread to most countries. Social distancing is the best procedure to prevent infection. Screening the available database conta...
Saved in:
Main Authors: | Israa Mohamed Shamkh (Author), Dina Pratiwi (Author), Hanaa S. Omar (Author), Nour El-Houda A. Reyad (Author) |
---|---|
Format: | Book |
Published: |
Institute for Researches and Community Services Universitas Muhammadiyah Palangkaraya,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum to "Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Different Coronavirus Spike Protein and ACE2" [J Mol Docking. 2021;1(2):1-14]
by: Israa Mohamed Shamkh, et al.
Published: (2021) -
Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Different Coronavirus Spike Protein and ACE2
by: Israa Mohamed Shamkh, et al.
Published: (2021) -
Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
by: Tiziana Ginex, et al.
Published: (2021) -
Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
by: Mohammad Z. Ahmed, et al.
Published: (2021) -
Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
by: Hualou Liang, et al.
Published: (2021)